|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current and future pharmacological therapies for managing cirrhosis and its complications显示文摘Due to the restrictions of liver transplantation,complication-guided pharmacological therapy has become the mainstay of long-term management of cirrhosis.This article aims to provide a complete overview of pharmacotherapy options that may be commenced in the outpatient setting which are available for managing cirrhosis and its complications,together with discussion of current controversies and potential future directions.PubMed/Medline/Cochrane Library were electronically searched up to December 2018 to identify studies evaluating safety,efficacy and therapeutic mechanisms of pharmacological agents in cirrhotic adults and animal models of cirrhosis.Non-selective betablockers effectively reduce variceal re-bleeding risk in cirrhotic patients with moderate/large varices,but appear ineffective for primary prevention of variceal development and may compromise renal function and haemodynamic stability in advanced decompensation.Recent observational studies suggest protective,haemodynamically-independent effects of beta-blockers relating to reduced bacterial translocation.The gut-selective antibiotic rifaximin is effective for secondary prophylaxis of hepatic encephalopathy;recent small trials also indicate its potential superiority to norfloxacin for secondary prevention of spontaneous bacterial peritonitis.Diuretics remain the mainstay of uncomplicated ascites treatment,and early trials suggest alpha-adrenergic receptor agonists may improve diuretic response in refractory ascites.Vaptans have not demonstrated clinical effectiveness in treating refractory ascites and may cause detrimental complications.Despite initial hepatotoxicity concerns,safety of statin administration has been demonstrated in compensated cirrhosis.Furthermore,statins are suggested to have protective effects upon fibrosis progression,decompensation and mortality.Evidence as to whether proton pump inhibitors cause gut-liver-brain axis dysfunction is conflicting.Emerging evidence indicates that anticoagulation therapy reduces incidence and increases recanalisation rates of non-malignant portal vein thrombosis,and may impede hepatic fibrogenesis and decompensation.Pharmacotherapy for cirrhosis should be implemented in accordance with up-to-date guidelines and in conjunction with aetiology management,nutritional optimisation and patient education. | David Kockerling Rooshi Nathwani Roberta Forlano Pinelopi Manousou Benjamin H Mullish Ameet Dhar | 2019 | World Journal of Gastroenterology2019，25，8： | 16 |
| 2 | Sustained high-level expression of human factor IX (hFIX) after livertargeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques显示文摘 | Nathwani AC Davidoff AM Hanawa H | 2002 | Blood2002，100，5： | 1 |
| 3 | In vitro uuspal de- flection and mieroleakage of maxillary premolars restored with novel low-shrink dental composites显示文摘 | Palin WM Fleming GJ Nathwani H | 2005 | Dent Mater2005，21，4： | 1 |
| 4 | Sustained high-level expression of human factorⅨ(h FIX)after liver-targeted delivery of recombinant adeno-associated virus encoding the h FIX gene in rhesus macaques显示文摘 | Nathwani AC Davidoff AM Hanawa H | 2002 | Blood2002，100，5： | 1 |
| 5 | Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38-subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV显示文摘 | Nathwani AC Hanawa H Vandergriff J | 2000 | Gene Ther2000，7，3： | 1 |
| 6 | Sustained high-lev?el expression of human factor IX (hFIX) after liver-targeted de?livery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques显示文摘 | Nathwani AC Davidoff AM Hanawa H | 2002 | Blood2002，100，5： | 1 |
| 7 | Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood显示文摘 | Kelly P F Nathwani A C Persons D A Vandergriff J A Hargrove P Vanin E F Nienhuis A W | 2002 | Mol Ther2002，5，3： | 1 |
| 8 | Pneumonia caused bymethicillin-resistant Staphylococcus aureus 显示文摘 | Rubinstein E Kollef M H Nathwani D | 2008 | Clin Infect Dis2008，465，5： | 1 |
| 9 | In vitro cuspal de- flection and microleakage of maxillary premolars restored with novel low-shrink dental composites显示文摘 | Palin WM Fleming GJ Nathwani H | 2005 | Dent Mater2005，21，4： | 1 |
| 10 | Malignant lymphoma arising in angioimmuno-blastic lymphadenopathy显示文摘 | Nathwani BN Rappaport H Kim H | 1978 | Cancer1978，41，2： | 1 |
| 11 | Acute myeloblastic leukemia developing in patients with mediastinal lymphoblastic lymphoma显示文摘 | Kjeldsberg CR Nathwani BN Rappaport H | | 0，，： | 1 |
| 12 | A clinicopathol study of 16cases显示文摘 | Weisenberger DD Nathwani BN Winberg CD and Rappaport H Multicentric angiofollicular lymph node hyperplasia | 1985 | Hum pathol1985，16，： | 1 |
| 13 | Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood显示文摘 | Hanawa H Kelly PF Nathwani AC | 2002 | Mol Ther2002，5，： | 1 |
| 14 | Classification of non-Hodgkin lymphomas in Guatemala according to the World Health Organization system 显示文摘 | Perry AM Molina Kitsch H Nathwani t]N | 2011 | Leuk Lymphoma2011，52，9： | 1 |
| 15 | Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcarefacilityacquired infection显示文摘 | Wiegand P N Nathwani D Wilcox M H | 2012 | J Hosp Infect2012，81，1： | 1 |
| 16 | comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood显示文摘 | HANAWA H KELLY P F NATHWANI A C | | 0，，： | 1 |
| 17 | Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated vira vector preparations that are free of helper virus and wild-type AAV 显示文摘 | Nathwani AC Hanawa H VandergriffJ | 2000 | Gene Ther2000，7，3： | 1 |
| 18 | In vitro cuspal deflection and microleakage of maxillary premolars restored with novel low-shrink dental composites显示文摘 | Palin WM Fleming GJ Nathwani H | | 0，，04： | 1 |
| 19 | In vitro cuspal deflection and microleakage of maxillary premolars restored with novel low-shrink dental composites显示文摘 | Palin WM Fleming GJ Nathwani H | 2005 | Dent Mater2005，21，4： | 1 |
| 20 | Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood显示文摘 | Hanawa H Kelly PF Nathwani AC | 2002 | Mol Ther2002，5，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员